Oral Intake of Rosiglitazone Promotes a Central Antihypertensive Effect Via Upregulation of Peroxisome Proliferator-Activated Receptor-γ and Alleviation of Oxidative Stress in Rostral Ventrolateral Medulla of Spontaneously Hypertensive Rats
Authors:
- 1 June 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 55 (6) , 1444-1453
Abstract
Rosiglitazone, a synthetic ligand of transcription factor peroxisome proliferator-activated receptor-γ (PPAR-γ), possesses a blood pressure–lowering effect beyond insulin sensitizing and glucose lowering. Oxidative stress in rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons for the maintenance of neurogenic vasomotor tone are located, contributes to neural mechanisms of hypertension. Activation of PPAR-γ protects against oxidative stress in RVLM by upregulation of mitochondrial uncoupling protein 2 (UCP2). We tested the hypothesis that oral intake of rosiglitazone exerts a central antihypertensive effect by ameliorating oxidative stress in RVLM via transcriptional upregulation of UCP2 after PPAR-γ activation. In adult spontaneously hypertensive rats but not normotensive Wistar-Kyoto rats, oral intake of rosiglitazone for 1 week resulted in vasodepression and a reduction in the vasomotor components of the systemic arterial pressure spectrum, our experimental index for sympathetic vasomotor tone. These antihypertensive effects of rosiglitazone in spontaneously hypertensive rats were abrogated by microinjection bilaterally into RVLM of PPAR-γ small interfering RNA. Oral intake of rosiglitazone also upregulated UCP2 and ameliorated the heightened superoxide anion level in RVLM of spontaneously hypertensive rats. Protection against oxidative stress in RVLM by rosiglitazone was abrogated by PPAR-γ small interfering RNA or by antisense oligonucleotide againstucp2mRNA. Gene knockdown ofucp2in RVLM also reversed the antihypertensive effect of rosiglitazone. These results suggest that oral intake of rosiglitazone promotes a central antihypertensive effect by decreasing sympathetic vasomotor activity through a PPAR-γ–dependent protection against oxidative stress in RVLM via transcriptional upregulation of the mitochondrial UCP2.Keywords
This publication has 52 references indexed in Scilit:
- Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: Are the reagents beneficial or harmful?International Journal of Cardiology, 2008
- PPARγ in the control of brown adipocyte differentiationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced ObesityHypertension, 2004
- Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitusAmerican Journal of Hypertension, 2003
- Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive PatientsDiabetes Care, 2003
- Peroxisome Proliferator–Activated Receptor γ and Metabolic DiseaseAnnual Review of Biochemistry, 2001
- Insulin Resistance and Its Treatment by ThiazolidinedionesRecent Progress in Hormone Research, 2001
- The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.Diabetes, 1999
- The Peroxisome Proliferator‐activated Receptors: Ligands and ActivatorsaAnnals of the New York Academy of Sciences, 1996
- Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.Journal of Clinical Investigation, 1995